Chester County News and Community Website
MALVERN, PA — The U.S. Food and Drug Administration granted Regenerative Medicine Advanced Therapy designation to Ocugen Inc.’s experimental OCU410 gene therapy for geographic atrophy, giving the blindness treatment access …
FDA Gives Ocugen Gene Therapy Expedited Regulatory Status Read More
WASHINGTON, D.C. — The Department of Health and Human Services said the Trump administration has adopted a government-wide policy prohibiting federal funding for what it defines as dangerous gain-of-function research …
HHS Bars Federal Funding for High-Risk Gain-of-Function Research Read More
MALVERN, PA — MAXONA Pharmaceuticals has received U.S. Food and Drug Administration clearance to begin a Phase 2 clinical trial of its investigational non-opioid pain therapy, advancing the company’s effort …
FDA Clears MAXONA Pain Drug for Phase 2 Trial Read More
WEST CHESTER, PA — Molecular Targeting Technologies Inc. (MTTI) will present clinical data from 81 patients at the 5th Targeted Radiopharmaceuticals Summit, offering evidence that its Evans Blue drug delivery …
MTTI to Present 81-Patient Radiopharma Data at Oncology Summit Read More
MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) has completed enrollment in its pivotal Phase 3 Alzheimer’s disease trial, positioning the biotechnology company for two planned U.S. regulatory submissions beginning …
Annovis Completes Enrollment for Alzheimer’s Phase 3 Trial Read More
WAYNE, PA — Teleflex Inc. (NYSE: TFX) has begun enrolling patients in a global pivotal study of its Freesolve resorbable magnesium scaffold, advancing the company’s effort to bring a temporary …
Teleflex Launches Pivotal Trial for Resorbable Heart Scaffold Read More
EXTON, PA — Lungpacer Medical Inc. said a study involving 50 organ donors found that temporary diaphragm neurostimulation improved donor lung function and increased the number of lungs available for …
Lungpacer Study Links Neurostimulation to Higher Lung Transplant Rates Read More
WEST CHESTER, PA — Verrica Pharmaceuticals (Nasdaq: VRCA) has dosed the first U.S. patient in a second Phase 3 clinical trial evaluating YCANTH for common warts, expanding a late-stage development …
Verrica Advances Wart Treatment Program With Phase 3 Trial Expansion Read More
WAYNE, PA — Palvella Therapeutics (Nasdaq: PVLA) has received U.S. Food and Drug Administration authorization for rolling review of its New Drug Application for QTORIN rapamycin, a step that could …
Palvella Secures FDA Rolling Review for Rare Disease Drug Read More
PHOENIXVILLE, PA — PleoPharma has dosed the first patient in a Phase 3 clinical trial of an investigational treatment for cannabis withdrawal symptoms, advancing a drug candidate that could become …
PleoPharma Begins Phase 3 Trial for Cannabis Withdrawal Drug Read More